MarketResearchNest.com adds “Global Human Immunodeficiency Virus (HIV) Rapid Test Kits Market 2017-2021” new report to its research database. The report spread across 75 pages with table and figures in it.
Research analysts forecast the global human immunodeficiency virus (HIV) rapid test kits market to grow at a CAGR of 7.23% during the period 2017-2021.
About Human Immunodeficiency Virus (HIV) Rapid Test Kits
HIV rapid test kits help in determining the presence of antibodies for HIV in body fluids. The test kits include simple, single-use, disposable devices that can provide results within limited time. These devices are designed for using unprocessed specimens such as saliva and blood to detect antibodies. Based on the test, the HIV rapid test kits are of two types, namely, rapid immunoassay test and rapid molecular diagnostic test.
Covered in this report
The report covers the present scenario and the growth prospects of the global human immunodeficiency virus (HIV) rapid test kits market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
Browse full table of contents and data tables at
The market is divided into the following segments based on geography:
Technavio’s report, Global Human Immunodeficiency Virus (HIV) Rapid Test Kits Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Human Immunodeficiency Virus (HIV) Rapid Test Kits Market 2017-2021
Technavio recognizes the following companies as the key players in the global human immunodeficiency virus (HIV) rapid test kits market: F. Hoffmann-La Roche, and Alere.
Other Prominent Vendors in the market are: Abbott, AccuBioTech, Access Bio, Ameritek, ALL.DIAG, Atomo Diagnostics, Autobio Diagnostics, Beckman Coulter, BD Biosciences, Bionor, Bio Focus, Bio-Rad Laboratories, bioMérieux, Bundi International Diagnostics, Calypte Biomedical, CS Innovation, Cortez Diagnostics, EY Laboratories, Hangzhou Biotest Biotech, Hema Diagnostics System, Hologic, JAL Innovation, LifeSign , Maccura Biotechnology, MedMira, Medinostics, MPI Diagnostics, Nectar Lifesciences, NTBIO Diagnostics, OraSure Technologies, PointCare, Premier Medical, Qiagen, Savyon Diagnostics, Shanghai Kehua Bioengineering, Span Diagnostics, Sysmex, Trinity Biotech, Turklab Tibbi Malzemeler San. Tic., ViennaLab Diagnostics, Voxtur Bio, and Wama Diagnostica.
Commenting on the report, an analyst from Research team said: “One trend in the market is growing preference for self-testing. HIV self-testing in home setting only marks the presence of HIV-1/2 antibodies or the HIV-1 p24 antigen, it does not provide diagnosis. The self-testing kit has an inbuilt control line, which makes the performance of the test accurate and reliable. The increasing preference for the self-testing procedure will drive the adoption of the HIV rapid test kits among people.”
Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=263078
According to the report, one driver in the market is some favorable reimbursements in developed countries. The favorable reimbursement scenario is an important contributor to the market growth. The US, Australia, and some countries in the EU are offering limited reimbursement coverage for laboratory testing. For instance, in the US, the Florida Individual Health Insurance Plans Preventive Services Coverage for HIV Testing is offered by both public and private payors, namely Aetna, AvMed, CIGNA, UnitedHealthcare, Humana, and Medicaid, for its citizens. Reimbursements offered by insurance companies to the end-users help in increasing the market adoption and expanding business geographically.
Further, the report states that one challenge in the market is high accuracy of ELISA over HIV rapid test kits. One of the market constraints for the HIV rapid test kits are the false results, which proves the inefficiency of these kits. This has largely impacted the adoption of HIV rapid test kits negatively. According to a NCBI study conducted by the Department of Microbiology, Maulana Azad Medical College, India, revealed that in 2014, the detection of HIV status by using HIV rapid test kits were poor than ELISA. The study was conducted with the help of SD Bioline HIV-1/2 3.0 and Microlisa-HIV, where 787 serum samples were tested for anti-HIV antibodies.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Key questions answered in this report: What will the market size be in 2021 and what will the growth rate be; What are the key market trends; What is driving this market; What are the challenges to market growth; Who are the key vendors in this market space; What are the market opportunities and threats faced by the key vendors; What are the strengths and weaknesses of the key vendors;
Enquiry before Buying at
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on industries, organizations, products, and trends.
Mr. Jeet Jain